STAGREL-A & A75 Tablets

 Diminishes the risk of cardiac insuffuciency

 

COMPOSITION:

  • Stagrel-A: Clopidogrel 75 mg + Aspirin IP 150 mg
  • Starel-A75: Clopidogrel 75 mg + Aspirin IP 75 mg
  • Improves inflammatory responses, accelerates platelet function & blood coagulation system after coronary artery bypass grafting.
  • Addition of clopidogrel decreases mortality rates by reducing the incidence of thrombotic vascular events in patients with congestive heart failure.
  • Reduces the risk of stroke and also does not increase the risk of hemorrhage in patients with transient ischemic attack.
  • Markedly inhibits (ADP)-mediated platelet aggregation and collagen-induced aggregation in patients with myocardial infarction.

INDICATIONS:

  • Acute & chronic coronary syndrome
  • Thromboembolic Stroke
  • Recurrent Ischemic Stroke
  • Myocardial Infarction
  • Angina
  • Atherosclerosis

Clopidogrel 

  • Drug class: Antiplatelet medications
  • Clopidogrel is a prodrug, which needs to be metabolized in the liver into active metabolites.
  • Clopidogrel efficiently reduces ADP-induced platelet aggregation (a key phenomenon in atherosclerosis & CVD) and prolongs bleeding time and is a safe and efficacious antiplatelet drug

Aspirin 

  • Drug Class: NSAIDs
  • The most widely tested antiplatelet regimen was aspirin.The benefit of low-dose aspirin therapy for the secondary prevention of serious cardiovascular events is clear.
  • Aspirin has long been the therapeutic foundation of the secondary prevention of CVD, to which contemporary drugs such as statins, and other antithrombotics have been added.

Combination:

  • Aspirin and clopidogrel are antiplatelet agents that display good antithrombotic activity.Clopidogrel in combination with aspirin is the current “gold standard” for reducing cardiovascular events.
  • Clopidogrel plus aspirin can reduce the relative risk of adverse cardiovascular events by 20%, compared with aspirin alone.